September 14, 2023 Conclusion of an amendment to global License Agreement with Menarini Group
Read More
September 13, 2023 Ryvu Therapeutics H1 2023 Financial Report
Read More
August 4, 2023 Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology
Read More
July 31, 2023 Conclusion of a financing agreement with the Medical Research Agency
Read More
July 31, 2023 Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology
Read More
July 21, 2023 Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
July 14, 2023 Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
Read More
July 6, 2023 Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
Read More
June 19, 2023 Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company
Read More
June 14, 2023 Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.
Read More
Posts navigation
